

IN THE CLAIMS

Please cancel claims 1-12 without prejudice to Applicant's right to pursue the subject matter of these claims in a future application, and add new claims 13-15 as follows:

1-12. (Cancelled)

13. (New) A method for treating a host infected with a human immunodeficiency virus (HIV) comprising exposing said host to an amount of HIV vector effective to inhibit HIV replication, and a biologically acceptable carrier, excipient and diluent,

wherein the HIV vector has an intact 5' HIV LTR, a lentiviral packaging signal sequence that comprises the leader sequence downstream of the LTR and until the beginning of the gag gene, and the rev response element,

wherein the HIV vector has 124 base pairs of nef sequences upstream of the 3' LTR replaced with a polylinker,

and wherein the HIV vector lacks a transgene.

14. (New) The method of claim 13, wherein the HIV is HIV-1.

15. (New) The method of claim 13, wherein the HIV of the host infection is HIV-1.